From our Sept. 15 issue: Has...
Not all biomarkers are the same....
Sandoz’s filgrastim could be a good...
From our Sept. 15 issue: Thanks...
W. Kelley Thomas, Ph.D., is director at the Hubbard Center for Genome Studies and a professor at the department of Molecular, Cellular and Biomedical Science, University of New Hampshire.
Do you think that biopharma companies should not have to go through the normal drug approval process in order to get potential life-saving therapies to Ebola patients more quickly?
Be sure to add email@example.com
to your Address Book or Safe Senders List.
here for instructions.
If you have any questions about your subscription, click
here to email us or call at (914) 740-2189.
You may also be interested in subscribing to the GEN magazine, an indispensable
resource for everyone involved in the business of translating discoveries at the
bench into solutions that fight disease and improve health, agriculture, and the
today to see why over 60,000 biotech professionals read GEN to
keep current in the areas of genomics, proteomics, drug discovery, biomarker discovery,
bioprocessing, molecular diagnostics, collaborations, biotech business trends, and
© 2014 Genetic Engineering & Biotechnology News All Rights Reserved